Niels Svenstrup - PepGen Manufacturing Chemistry
| PEPG Stock | USD 4.32 0.08 1.82% |
Insider
Niels Svenstrup is Manufacturing Chemistry of PepGen
| Age | 54 |
| Address | 321 Harrison Avenue, Boston, MA, United States, 02118 |
| Phone | 781 797 0979 |
| Web | https://pepgen.com |
Latest Insider Transactions
Niels Svenstrup Latest Insider Activity
Tracking and analyzing the buying and selling activities of Niels Svenstrup against PepGen stock is an integral part of due diligence when investing in PepGen. Niels Svenstrup insider activity provides valuable insight into whether PepGen is net buyers or sellers over its current business cycle. Note, PepGen insiders must abide by specific rules, including filing SEC forms every time they buy or sell PepGen'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Niels Svenstrup over six months ago Disposition of 10000 shares by Niels Svenstrup of PepGen at 13.41 subject to Rule 16b-3 |
PepGen Management Efficiency
The company has return on total asset (ROA) of (0.352) % which means that it has lost $0.352 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6626) %, meaning that it created substantial loss on money invested by shareholders. PepGen's management efficiency ratios could be used to measure how well PepGen manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.58. The current Return On Capital Employed is estimated to decrease to -0.71. At this time, PepGen's Debt To Assets are most likely to slightly decrease in the upcoming years.Similar Executives
| Showing other executives | INSIDER Age | ||
| MD MPH | MediciNova | 56 | |
| David Elmaleh | PureTech Health PLC | 76 | |
| Bennett MD | PureTech Health PLC | 84 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Piyush Patel | Tyra Biosciences | 58 | |
| , Langer | PureTech Health PLC | 75 | |
| Deepika PharmD | Pmv Pharmaceuticals | 47 | |
| Lauren White | C4 Therapeutics | N/A | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| MD FACP | AN2 Therapeutics | 76 | |
| Steve Andre | Cullinan Oncology LLC | N/A | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
| Jennifer Michaelson | Cullinan Oncology LLC | 57 | |
| Yuichi MD | MediciNova | 74 | |
| Vered MBA | Compass Therapeutics | 53 | |
| Allison Talbot | PureTech Health PLC | N/A | |
| Winston MBA | Pmv Pharmaceuticals | 48 | |
| Jason CPA | MediciNova | 46 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Gregory Russotti | Century Therapeutics | 57 | |
| Anne Lesage | Pharvaris BV | 63 | |
Management Performance
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.35 |
PepGen Leadership Team
Elected by the shareholders, the PepGen's board of directors comprises two types of representatives: PepGen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PepGen. The board's role is to monitor PepGen's management team and ensure that shareholders' interests are well served. PepGen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PepGen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James McArthur, CEO and President | ||
| Caroline Godfrey, Founder Member | ||
| Afsaneh Mohebbi, Senior Management | ||
| Michelle MD, Senior Development | ||
| David CFA, Senior Communications | ||
| Jaya Goyal, Executive Development | ||
| Hayley Parker, Senior Affairs | ||
| Sonia DPHIL, VP Operations | ||
| Michael Gait, Founder Member | ||
| Jennifer Cormier, VP Operations | ||
| Mary DeLena, General Secretary | ||
| Mary JD, General Secretary | ||
| Kyle Breidenstine, VP Controller | ||
| Emiko Bryant, Chief Staff | ||
| Noel MBA, Chief Officer | ||
| Niels Svenstrup, Manufacturing Chemistry |
PepGen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PepGen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | 21 M | ||||
| Shares Outstanding | 32.6 M | ||||
| Shares Owned By Insiders | 0.02 % | ||||
| Shares Owned By Institutions | 92.55 % | ||||
| Number Of Shares Shorted | 802.57 K | ||||
| Price To Book | 1.02 X | ||||
| EBITDA | (83.58 M) | ||||
| Net Income | (78.63 M) |
Currently Active Assets on Macroaxis
When determining whether PepGen is a strong investment it is important to analyze PepGen's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact PepGen's future performance. For an informed investment choice regarding PepGen Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PepGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in PepGen Stock please use our How to Invest in PepGen guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PepGen. If investors know PepGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PepGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.98) | Return On Assets (0.35) | Return On Equity (0.66) |
The market value of PepGen is measured differently than its book value, which is the value of PepGen that is recorded on the company's balance sheet. Investors also form their own opinion of PepGen's value that differs from its market value or its book value, called intrinsic value, which is PepGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PepGen's market value can be influenced by many factors that don't directly affect PepGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PepGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if PepGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PepGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.